VM 26 in advanced mycosis fungoides.
Five consecutive patients with progressive extracutaneous stage IV mycosis fungoides (MF) were treated with VM 25, 100 mg/m2 i.v., for at least 3 cycles. All patients had been extensively pretreated and in particular with vinca alkaloids. Two partial responses of 5 and 9+ months duration and 1 minimal response of 5 months duration were obtained. Transient myelosuppression was encountered in all patients. These preliminary results should encourage further exploration of VM 26, even in less advanced MF.
D000328:Adult; D000368:Aged; D001855:Bone Marrow Diseases / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009182:Mycosis Fungoides / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013160:Splenic Neoplasms / Q000188:drug therapy*; D013713:Teniposide / Q000627:therapeutic use*
D013713:Teniposide; D011034:Podophyllotoxin